Dennis Scanlon, PhD, professor of health policy and administration at Penn State University, says that it is important to consider what details patients need in order to make informed decisions. For payers, this might include informing consumers about enrollment decisions.
Dennis Scanlon, PhD, professor of health policy and administration at Penn State University, says that it is important to consider what details patients need in order to make informed decisions. For payers, this might include informing consumers about enrollment decisions. The health plan decisions that patients make during an enrollment period can have implications down the road.
“We need to get people to think about not only what the price is to enroll today, but what the implications may be in the future should the need arise for care,” says Dr Scanlon. He notes that consumers’ other lifestyle concerns, such as their retirement savings, may also shape their decision making. “[If] I’m healthy today I may want to go with a lower price option, but in doing so, I might be making decisions that ultimately that could impact me or adversely impact my decision down the road should I need significant care.”
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
The Legal Architecture of Psychedelic Therapy: Risks, Responsibilities, and Reimbursement Realities
July 30th 2025Key legal, ethical, and compliance considerations for managed care professionals navigating the evolving landscape of psychedelic-assisted therapy include regulatory risks, data privacy challenges, reimbursement limitations, and the need for culturally informed care models.
Read More